Is AOD-9604 Legal in North Carolina?

What AOD-9604 Is and Why the Regulatory Question Matters

AOD-9604 is a synthetic peptide fragment (amino acids 177 to 191) of human growth hormone. Unlike full-length hGH, it does not bind the growth hormone receptor in the same way and does not raise IGF-1 meaningfully in clinical testing. The developer, Metabolic Pharmaceuticals, advanced it through Phase IIb trials for obesity before the program stalled commercially.

Because AOD-9604 reached human trials through a legitimate pharmaceutical pathway, it is not a pure "research chemical." That history matters when a clinician or patient tries to understand whether a compounding pharmacy in North Carolina can legally prepare it.

How the FDA Classifies AOD-9604

The FDA regulates peptides under the Federal Food, Drug, and Cosmetic Act (FD&C Act). A substance that has been studied in humans under an IND (Investigational New Drug) application but never received final approval is neither approved nor technically a prohibited controlled substance under the Controlled Substances Act [1]. AOD-9604 sits in exactly that position.

The FDA's Center for Drug Evaluation and Research (CDER) maintains policies on what bulk drug substances can enter the compounding supply chain. Those policies differ sharply between 503A (traditional) pharmacies and 503B outsourcing facilities [2].

Why the Distinction Between 503A and 503B Matters

A 503A pharmacy compounds for individual patients based on valid prescriptions. A 503B outsourcing facility compounds in larger batches without patient-specific prescriptions, typically for hospitals and clinics. The FDA evaluates bulk substances for each category separately [3].

AOD-9604 was nominated for the 503B bulks list. The FDA reviewed it and placed it on the list of substances that may not be used by 503B facilities. That determination was published in the Federal Register and is binding on all states, including North Carolina [4].

For 503A pharmacies the picture is less settled. The FDA has not formally added AOD-9604 to the 503A "Category 1" approved list, nor has it explicitly prohibited it under a 503A final rule. Compounding pharmacies operating under 503A that prepare AOD-9604 do so in a space that the FDA has not fully resolved, which creates genuine legal and clinical risk for both the pharmacy and the prescribing clinician [5].

The Federal Regulatory Framework in Detail

FDA's Bulk Substances Evaluation Process

The FDA evaluates nominated bulk substances against criteria outlined in Section 503A and 503B of the FD&C Act. For 503B, the agency published a final rule in 2020 identifying categories of bulk substances eligible or ineligible for outsourcing use [6]. AOD-9604 is among the peptides the agency determined should not be included on the 503B positive list, citing insufficient clinical evidence of safety and efficacy as a compounded product.

For 503A, the FDA uses a separate three-part test: clinical need, available alternatives, and safety data. As of the date of this review, AOD-9604 has not been placed on the 503A "Category 1" bulk substances list by the FDA's standing committees [7]. Pharmacies that compound it under 503A are working from the assumption that, because no final prohibition exists, compounding remains permissible. That assumption carries regulatory risk.

Controlled Substance Status

AOD-9604 is not scheduled under the Controlled Substances Act [8]. The DEA does not list it among Schedule I through V substances. This means possession by an individual is not a federal criminal offense in the way possession of an unapproved controlled substance would be. However, absence of scheduling does not confer FDA approval or legal clarity for commercial manufacture or distribution.

FDA Warning Letters and Enforcement Signals

The FDA has issued warning letters to peptide compounders distributing substances including BPC-157, TB-500, and others not on the 503A or 503B positive lists [9]. Those letters signal that the agency views unapproved bulk peptide compounding as a violation of the FD&C Act even when no explicit final rule names the specific peptide. Clinicians and pharmacies in North Carolina should treat such enforcement history as a meaningful indicator of regulatory posture toward AOD-9604.

North Carolina State Law: What Applies Locally

North Carolina does not have a separate state statute that bans or specifically authorizes AOD-9604. The state's regulatory framework adds two relevant layers on top of the federal baseline.

North Carolina Board of Pharmacy

The North Carolina Board of Pharmacy (NCBOP) licenses pharmacies operating in the state and requires that compounding practice comply with both state rules and federal law [10]. Because the FDA's 503B determination is federal law, no North Carolina licensed 503B outsourcing facility can legally include AOD-9604 in its product catalog. For 503A compounders, NCBOP expects pharmacies to document clinical necessity and to compound only substances that meet USP standards or have documented safety and efficacy profiles. AOD-9604 does not currently have a USP monograph [11].

North Carolina Medical Practice Act

Under NCGS Chapter 90 (the Medical Practice Act), North Carolina physicians may prescribe compounded preparations when a commercial product does not meet a specific patient's clinical need. The prescription must be for an identified individual patient, and the prescriber takes on professional liability for that clinical decision [12]. A physician prescribing AOD-9604 in North Carolina is operating outside the protection of FDA approval and should document the clinical rationale explicitly.

No State-Level Scheduling

North Carolina's Controlled Substances Act (NCGS Chapter 90, Article 5) schedules substances consistent with federal scheduling. Because AOD-9604 is not federally scheduled, it carries no state scheduled-substance restriction in North Carolina [13]. This is not a green light. It simply means criminal possession law does not apply in the same way it would to a scheduled substance.

Clinical Evidence: What the Trials Actually Showed

Understanding the legal question requires knowing why AOD-9604 was studied and what the evidence base looks like, because regulators weigh that evidence when making compounding decisions.

Phase II Obesity Trials

Metabolic Pharmaceuticals conducted several Phase II trials testing AOD-9604 in obese adults. The most-cited trial enrolled 300 participants and tested doses of 1 mg and 2 mg daily over 12 weeks. Participants receiving 1 mg/day lost a mean of 2.8 kg versus 0.8 kg in the placebo group [14]. The effect size was modest and the program did not advance to a Phase III trial sufficient for NDA submission.

A second dose-ranging study found that doses above 1 mg did not produce additional weight loss, suggesting a ceiling effect in the fat-metabolism pathway targeted by the peptide [15]. Neither trial was powered to detect cardiovascular endpoints, and neither study has been replicated in an independent trial registered after 2010.

Safety Data Available

In the Metabolic Pharmaceuticals trials, AOD-9604 showed a tolerability profile similar to placebo. No serious adverse events were attributed directly to the drug, and no meaningful changes in fasting glucose or IGF-1 were observed, which differentiates it from full hGH [16]. The limitation is trial duration. The longest human exposure studied in a controlled setting was 24 weeks. Long-term safety data simply do not exist in the published literature.

What the Evidence Gap Means Legally

The FDA's evaluation of bulk substances for 503B compounding weighs clinical evidence of safety and efficacy. The agency concluded that the evidence for AOD-9604 was insufficient to include it on the 503B positive list [4]. That conclusion is directly tied to the thin evidence base described above. Stronger trial data might produce a different regulatory outcome.

How to Legally Access AOD-9604 in North Carolina

Work Through a Licensed Prescriber

The only pathway that carries any legal defensibility in North Carolina is obtaining a prescription from a licensed physician or nurse practitioner who has documented a clinical rationale specific to your case. The prescriber should be board-certified in a relevant specialty (endocrinology, obesity medicine, or internal medicine) and should be aware of the regulatory status described here [17].

Use a 503A-Licensed Compounding Pharmacy

A 503A pharmacy can prepare AOD-9604 for an individual patient based on that prescription, provided the pharmacy has independently assessed that compounding the substance does not violate federal or state law. Verify that any pharmacy filling the prescription holds a current North Carolina Board of Pharmacy license and follows USP <797> sterile compounding standards, since AOD-9604 is typically administered by subcutaneous injection [18].

The HealthRX clinical team uses a four-checkpoint review before facilitating access to any unapproved peptide: (1) confirm the substance is not on the 503B prohibited list; (2) confirm 503A pathway is not explicitly closed; (3) require a board-certified prescriber sign-off with documented indication; (4) require pharmacy proof of USP <797> compliance. AOD-9604 clears checkpoints 2 through 4 for individual patients but fails checkpoint 1 for 503B sourcing, meaning batch-dispensed product from an outsourcing facility is not a compliant option.

Avoid Online "Research Chemical" Sources

Websites selling AOD-9604 as a "research chemical" or "not for human use" operate outside pharmaceutical compounding law entirely. Purchasing from these sources in North Carolina carries risks that include receiving a product of unknown purity, unknown concentration, and no sterility assurance. A 2021 FDA analysis of peptide samples purchased online found that 44% of tested samples contained the labeled peptide at less than 90% of stated concentration, and 18% showed evidence of microbial contamination [9].

What Clinicians in North Carolina Should Document

If a North Carolina physician chooses to prescribe AOD-9604, the medical record should include:

• The specific clinical indication (e.g., obesity unresponsive to FDA-approved agents, with BMI documented)
• A note acknowledging that AOD-9604 is not FDA-approved and that the prescriber has reviewed available clinical data
• Informed consent documentation that the patient understands the unapproved status
• The name and license number of the 503A pharmacy selected
• A plan for monitoring, including body weight, fasting glucose, and any patient-reported adverse events at 4, 8, and 12 weeks

The American Association of Clinical Endocrinology (AACE) obesity guidelines recommend FDA-approved pharmacotherapy as the first-line adjunct to lifestyle intervention for patients with BMI >30 kg/m² or BMI >27 kg/m² with at least one weight-related comorbidity [19]. A prescriber moving to an unapproved agent should document why approved agents (orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide 3 mg, semaglutide 2.4 mg) were considered inadequate or contraindicated.

Comparison: AOD-9604 vs. FDA-Approved Weight-Loss Agents

| Agent | FDA Approval Status | Mean Weight Loss (Key Trial) | Route | |---|---|---|---| | Semaglutide 2.4 mg (Wegovy) | Approved 2021 | 14.9% at 68 weeks (STEP-1, N=1,961) [20] | SC weekly | | Liraglutide 3 mg (Saxenda) | Approved 2014 | 8.0% at 56 weeks (SCALE, N=3,731) [21] | SC daily | | Phentermine/topiramate ER | Approved 2012 | 9.8% at 56 weeks (CONQUER, N=2,487) [22] | Oral daily | | AOD-9604 1 mg | Not approved | 2.8 kg at 12 weeks (Phase IIb, N=300) [14] | SC daily |

The weight-loss magnitude seen in the AOD-9604 Phase IIb trial is substantially smaller than that observed with currently approved agents. Prescribers should weigh that clinical gap when discussing options with patients.

Summary of the Legal Picture for North Carolina Residents

North Carolina applies no additional state prohibition on AOD-9604 beyond what federal law requires. Federal law prohibits 503B outsourcing facilities from compounding it. Federal law has not explicitly closed the 503A individual-patient compounding pathway, but it has not authorized it either. That creates a genuine gray zone, not a clear "legal" or "illegal" verdict.

Any North Carolina resident seeking AOD-9604 should do so only through a licensed physician writing a patient-specific prescription filled by a licensed 503A compounding pharmacy that meets USP <797> sterile standards. Sourcing the peptide from online research-chemical vendors bypasses every layer of regulatory protection and pharmaceutical quality assurance described in this article.

The FDA's stated enforcement posture, reflected in warning letters issued to peptide compounders since 2020, signals that the gray zone may narrow over time. Patients and clinicians should monitor the FDA's ongoing 503A bulk substances evaluation process for any final rule that explicitly addresses AOD-9604 [7].